A SWOG prospective cohort study reported interim results on microRNA-371a-3p (miR371) as a relapse predictor in early-stage testicular cancer patients managed with active surveillance. The presentation at ASCO described high specificity and negative predictive value for miR371, but researchers flagged that clinical utility as a relapse biomarker remains unclear. Investigators from the SWOG Cancer Research Network (S1823/GCC.1) collected serial plasma samples after orchiectomy and stratified participants into low-, moderate-, and high-risk relapse groups, with miR371 assessed via real-time PCR over defined surveillance windows.